Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis
Authors
- Jianan Feng (ORCID: https://orcid.org/0000-0001-5139-1695)
- Zhoubin Feng (ORCID: https://orcid.org/0009-0001-5217-1835)
- Mingxin Pan (ORCID: https://orcid.org/0000-0002-3979-5571)
- Yuyan Xu (ORCID: https://orcid.org/0000-0003-3335-1248)
- Jingyuan Pei (ORCID: https://orcid.org/0000-0002-1973-1028)
- L. Wang (ORCID: https://orcid.org/0000-0001-7855-6728)
- Chuang Peng (ORCID: https://orcid.org/0000-0002-3701-1737)
- Yinghui Song (ORCID: https://orcid.org/0000-0002-6592-6678)
- Yaohong Wen
- Ding Bai (ORCID: https://orcid.org/0000-0002-5058-4329)
- Shuyi Zhou (ORCID: https://orcid.org/0000-0002-8349-0150)
- Lei Cai (ORCID: https://orcid.org/0000-0003-0935-1870)
- Sulai Liu (ORCID: https://orcid.org/0000-0002-5257-3922)
- Guolin He (ORCID: https://orcid.org/0000-0001-8032-1434)
- Cheng Zhang (ORCID: https://orcid.org/0000-0002-4570-1762)
- Chunming Wang (ORCID: https://orcid.org/0000-0003-0261-7920)
- Shunjun Fu (ORCID: https://orcid.org/0000-0001-5318-5908)
- Hongkun Tan
Institutions
- Hunan Provincial Center for Disease Control and Prevention (CN)
- Zhujiang Hospital (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1186/s12957-025-03767-5
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- National Natural Science Foundation of China
- Southern Medical University
- Basic and Applied Basic Research Foundation of Guangdong Province